Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-04-17
2009-06-02
Weber, Jon P (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S757000, C424S656000, C424S634000, C530S300000, C530S370000, C530S377000, C530S378000
Reexamination Certificate
active
07541329
ABSTRACT:
Compositions and methods for reducing hypercholesterolemia and, accordingly, the risk of cardiovascular disease, are provided. Such compositions may comprise isolated oil body associated proteins. Additionally provided are foodstuffs to which one or more oil body associated proteins have been added. The compositions employed in the invention may further comprise additive compounds, for example, a saponin, an isoflavone, a phospholipid, a carbohydrate substantially resistant to digestion, or a combination thereof. The methods and compositions of the invention may be used to lower cholesterol and other lipid levels in subjects to achieve a reduction in the risk of cardiovascular disease.
REFERENCES:
patent: 3642490 (1972-02-01), Hawley et al.
patent: 3694221 (1972-09-01), Hoer et al.
patent: 4360537 (1982-11-01), Tan et al.
patent: 5478585 (1995-12-01), Isono et al.
patent: 5559220 (1996-09-01), Roessler et al.
patent: 5830887 (1998-11-01), Kelly
patent: 5855892 (1999-01-01), Potter
patent: 5968516 (1999-10-01), Liu
patent: 6136367 (2000-10-01), Hoie
patent: 6171640 (2001-01-01), Bringe
patent: 2004/0014640 (2004-01-01), Kohno et al.
patent: 86105538 (1986-07-01), None
patent: 0 533 512 (2002-08-01), None
patent: 1 323 425 (2003-07-01), None
patent: 2001-114800 (2001-04-01), None
patent: 2002-101820 (2002-04-01), None
patent: WO 89/01495 (1989-02-01), None
patent: WO 00/30602 (2000-06-01), None
patent: WO 00/30663 (2000-06-01), None
patent: WO 01/36648 (2001-05-01), None
patent: WO 02/26243 (2002-04-01), None
patent: WO 02/26788 (2002-04-01), None
M.C. Berenbaum, Synergy, additivism and antagonism in immunosuppression, A critical review, Clin. Exp. Immunol, 1977, vol. 28, pp. 1-18.
M.C. Berenbaum, What is Synergy?, Pharmacological Reviews, 1989, vol. 1969, vol. 41, pp. 93-141.
Yamada, et al, Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hyperlipidemic rabbits, Proc. Natl. Acad. Sci. USA, Jan. 1989, vol. 86, pp. 665-669.
Hori, et al., Soy Protein Hydrolyzate with Bound Phospholipids Reduces Serum Cholesterol Levels in Hypercholesterolemic Adult Male Volunteers, Boisci. Biotechnol. Biochem., 2001, 65(1), pp. 72-78.
Lovati, et al/Manzoni, et al, Soybean Protein Products as Regulators of Liver Low-Density Lipoprotein Receptors I Identification of Active Beta-Conglycinin Subunits II Alpha and Alpha' Rich Commerical Soy Concentrate and Alpha' Deficient Mutant Differently Affect Low-Density Lipoprotein Activation, J Agric Food Chem., 1998, V 46, pp. 2474-2484.
M. Fiordaliso, et al., Dietary Oligofructose Lower Triglycerides, Phospholipids and Cholesterol in Serum and Very Low Density Lipoproteins of Rats, Lipids, 1995, vol. 30 No. 2, pp. 163-167.
J. Wojcicki, et al., Clinical Evaluation of Lecithin as a Lipid-lowering Agent, Phytotherapy Research, Dec. 1995, vol. 9, Iss. 8, pp. 597-599.
Tallarida, Ronald J., “Drug Synergism and Dose Effect Data Analysis”, (2000) Chapman & Hall/CRC, title page and table of contents provided.
Abell, “Targeting and topology of seed oleosins,” Ph.D. Dissertation, Department of Biological Sciences, Calgary, Alberta, Canada, May, 1999.
Anderson et al., “Meta-analysis of the effects of soy protein intake on serum lipids,”N Engl J Med, 333(5):276-282, 1995.
Anthony et al., “Neither isoflavones nor the alcohol-extracted fraction added to alcohol-washed soy protein isolate restores the lipoprotein effects of soy protein isolate,”4thInternational Symposium on the Role of Soy Preventing and Treating Chronic Disease, p. 35, San Diego, CA, Nov. 4-7, 2001.
Bringe and Cheng, “Low-fat, low-cholesterol egg yolk in food applications,”Food Tech, 49(5):94-106, 1995.
Bringe, , “Properties of low-fat, low cholesterol egg yolk prepared by supercritical CO2 extraction,”Adv Exp Med Biol, 415:161-181, 1997.
Clarkson et al., “A paradoxial association between plasma isoflavone concentrations on a soy-containing diet, and both plasma lipoproteins and atherosclerosis,”4thInternational Symposium on the Role of Soy Preventing and Treating Chronic Disease, p. 35, San Diego, CA, Nov. 4-7, 2001.
Forsythe et al., “Dietary protein effects on cholesterol and lipoprotein concentrations: a review,” J Am Coll Nutr, 5:533-549, 1986.
Fransen et al., “Oil bodies and their associated proteins, oleosin and caleosin,”Plysiol Plant, 112(3):301-307, 2001.
GenBank Accession No. AAA67699.
GenBank Accession No. AAA68065.
GenBank Accession No. AAA68066.
GenBank Accession No. CAA55348.
GenBank Accession No. P29530.
GenBank Accession No. P29531.
Hori et al., “Cholesterol-lowering effects of isolated soybean protein hydrolyzate with bound phospholipids in rats,”J Jpn Soc Nutr Food Sci, 52:135-145, 1999.
Hori et al., “Soy protetin hydrolyzate with bound phospholipids reduces serum cholesterol levels in hypercholesterolemic adult male volunteers,”Biosci Biotechnol Biochem, 65(1):72-78, 2001.
Huang, “Oleosins and oil bodies in seeds and other organs,” Plant Physiol, 110:1055-1061, 1996.
Iwami et al., “Characterization of a major bile acid-binding peptide from the peptic-pancreatic digest of soybean protein,”Soy Protein Res Com Japan, 15:74-80, 1994.
Iwami et al., “Molecular recognition of bile acids by soy protein and modeling of its mimetics,”English Title of the S.P.R.C. Reportvol. 22, abstract fromSoy Protein Research, Japan, 4:58-64, 2001.
Kanamoto et al., “Soybean ‘resistant protein’ that prevents colon and liver carcinogenesis induced by bile acids in rat,”4thInternational Symposium on the Role of Soy Preventing and Treating Chronic Disease, A-13, p. 42, San Diego, CA, Nov. 4-7, 2001.
Keenan, “Milk lipid globules and their surrounding membrane: a brief history and perspectives for future research,” J Mammary Gland Biol Neopasia, 6(3):365-371, 2001.
Leber et al.,Yeast, 10:1421-1428, 1994.
Lovati et al., “Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells,” J Nutr, 130:2543-2549, 2000.
Morita et al., “Resistant proteins alter cecal short-chain fatty acid profiles in rats fed high amylose cornstarch,”J Nutr, 128:1156-1164, 1998.
Murphy et al., “A class of amphipathic proteins associated with lipid storage bodies in plants. Possible similarities with animal serum apolipoproteins,”Biochim Biophys Acta, , 1088:86-94, 1991.
Nagaoka et al., “Identification of novel hypocholesterolemic peptides derived from bovine milk beta-lactoglobulin,”Biochem Biophys Res Comm, 281:11-17, 2001.
Nagaoka et al., “Soy protein peptic hydrolysate with bound phospholipids decreases micellar solubility and cholesterol absorption in rats and caco-2 cells,”J Nutr, 129:1725-1730, 1999.
Oakenfull, “Soy proteins, saponins and plasma cholesterol,” Letter to the Editor,J Nutr, 131:2971-2972, 2001.
Pieper-Fürst et al., “Purification and characterization of a 14-kilodalton protein that is bound to the surface of polyhydroxyalkanoic acid granules inRhodococcus ruber,” J Bacteriol, 176:4328-4337, 1994.
Potter, “Soy-new health benefits associated with an ancient food,” Nutrition Today, 35(2):53-60, 2000.
Roessler, J Phycol, “Effects of silicon deficiency on lipid composition and metabolism in the diatom cyclotella cryptica,” (London), 24:394-400, 1988.
Samoto et al., “Improvement of the off-flavor of soy protein isolate by removing oil-body associated proteins and polar lipids,”Biosci Biotechnol Biochem, 62(5):935-940, 1998.
Sitori et al., “Reduction of serum cholesterol by soy proteins: clinical experience and potential molecular mechanisms,”Nutr Metab Cardiovasc Dis, 8:334-340, 1998.
Sugano et al., “The hypocholesterolemic action of the undigested fraction of soybean protein in rats,”Atherosclerosis, 72:115-122, 1988.
Ting et al., “Oleosin of plant seed o
Bringe Neal A.
Karunanandaa Kanthasamy
Li Esq. Chunping
Mohamed Abdel A
Monsanto Technology LLC
Sonnenschein Nath & Rosenthal LLP
Weber Jon P
LandOfFree
Oil body associated protein compositions and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oil body associated protein compositions and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oil body associated protein compositions and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4060981